بسم الله الرحمن الرحيم This is the Saudi Myeloma Working group X page (SMWG)

Join us in the 3rd Saudi Myeloma Group annual meeting.

Are you ready for tomorrow’s event? Registration link: mercatus-pharma.com/form/transform…

Was a great pleasure to see Rahul Banerjee, MD, FACP speaking about his recent @BloodJournal publication for the Saudi Myeloma المجموعة السعودية لأبحاث المايلوما group. Thanks Rahul and see you in person soon :)

A proud moment! After 1.5 years of dedication, both Saudi Myeloma Guidelines—for NDMM and RR myeloma—have been officially accepted in CLML. A huge thank you to the outstanding team at the Saudi Myeloma Working Group. A national milestone for myeloma care in Saudi Arabia. 🇸🇦📄💪

Just out: FDA grants accelerated approval to linvoseltamab for treatment of relapsed/refractory myeloma. It is the 3rd BCMA bispecific antibody approved for myeloma. I welcome the choice that patients and physicians have. ajmc.com/view/fda-appro…

Before the end of 2025, Cilta-cel (CARVYKTI), a groundbreaking CAR-T cell therapy, launches in Saudi Arabia! Join us for an exclusive event on Sunday at 8 PM to learn how this innovative treatment is transforming lives for patients with relapsed or refractory MM.

CAR-T in Myeloma: the Saudi Guidelines. clinical-lymphoma-myeloma-leukemia.com/article/S2152-…

Join us for the Saudi Myeloma Working Group Virtual Series (Wave 8) 🗓️ Sunday, Aug 31 | 8 PM (KSA) | 2 CME 🎤 Prof. Shaji Kumar Shaji Kumar (Mayo Clinic) Topic: Positioning T-Cell Engagers in Relapsed/Refractory Myeloma 💻 Don’t miss it! us06web.zoom.us/webinar/regist…

A new webinar 🚨 linkedin.com/posts/ghazi-al…

Updated mSMART guidelines on treatment of newly diagnosed myeloma. Major change: For standard risk myeloma, doublet maintenance (lenalidomide plus anti CD38) recommended if MRD+ post transplant. msmart.org/mm-treatment-g…

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience nature.com/articles/s4140…